5 Key Trends in Orphan Drugs & Rare Diseases
Long regarded as a neglected backwater within the drug discovery landscape and the preserve of only a handful of niche players, the rare disease space has been undergoing an extraordinary…
Louis was the Senior Analyst and Editor-in-Chief from 2013 to 2019. He currently collaborates with PharmaBoardroom as external editor. Having directed pharmaceuticals & life science projects across 4 continents, he has published over 30 country reports as well as produced analytical studies on trends in blockchain, Pharma M&A and biotechnology. He has a professional background in consultan more...
Long regarded as a neglected backwater within the drug discovery landscape and the preserve of only a handful of niche players, the rare disease space has been undergoing an extraordinary…
The research areas in which Canada has the potential to excel are numerous, one being the world of genomics. The stem cell itself having been discovered in Canada, Marc LePage,…
Seizing the cost competitiveness of the Turkish market and the government’s nurturing of local manufacturing, Turkish companies are looking to harness their geographic positioning and export to developed and developing…
The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced…
South Korea’s proposed Moon Jae-In Care has been subject to both praise and protest this year. President Moon Jae-in’s plan dubbed “Moon Care” will be implemented in stages throughout 2022…
Takeda’s proposed acquisition of Shire may have come as a surprise to many commentators, but the appointment of an audacious French CEO in the form of Christophe Weber had already…
Ipsen CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come. “From our…
A sudden imposition of import restrictions on pharmaceuticals in 2017 has pushed several multinational companies to establish local production facilities in Algeria. However, the localization process can be fraught both…
The global drop in oil prices in 2015-2016 hit the Algerian economy – which is heavily reliant on petroleum revenues – hard. The country’s government implemented severe economic cuts across…
Multinational pharmaceutical companies are increasingly choosing Algeria as a base for their regional headquarters, despite the complexities of the local market. The representatives of Lilly, bioMérieux and Abbott in Algeria…
Spanish stakeholders have been trailblazing the concept of the “liquid hospital”, which envisions the virtual and physical expansion of healthcare provision beyond the parameters of the traditional centralized hospital structure.…
Cyprus is capitalizing on its well-established tourism infrastructure to stake a claim for itself as one of Europe’s premier medical tourism destinations. “I believe Cyprus can become a really important…
See our Cookie Privacy Policy Here
